Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

Glioblastoma, a brief review of history, molecular genetics, animal models and novel therapeutic strategies.

Agnihotri S, Burrell KE, Wolf A, Jalali S, Hawkins C, Rutka JT, Zadeh G.

Arch Immunol Ther Exp (Warsz). 2013 Feb;61(1):25-41. doi: 10.1007/s00005-012-0203-0. Epub 2012 Dec 7. Review.

PMID:
23224339
2.

Deregulated signaling pathways in glioblastoma multiforme: molecular mechanisms and therapeutic targets.

Mao H, Lebrun DG, Yang J, Zhu VF, Li M.

Cancer Invest. 2012 Jan;30(1):48-56. doi: 10.3109/07357907.2011.630050. Review.

3.

Molecular targeting of glioblastoma: Drug discovery and therapies.

Bai RY, Staedtke V, Riggins GJ.

Trends Mol Med. 2011 Jun;17(6):301-12. doi: 10.1016/j.molmed.2011.01.011. Epub 2011 Mar 14. Review.

4.

Glioblastoma: from molecular pathology to targeted treatment.

Cloughesy TF, Cavenee WK, Mischel PS.

Annu Rev Pathol. 2014;9:1-25. doi: 10.1146/annurev-pathol-011110-130324. Epub 2013 Aug 5. Review.

PMID:
23937436
5.

Molecular, histopathological, and genomic variants of glioblastoma.

Karsy M, Huang T, Kleinman G, Karpel-Massler G.

Front Biosci (Landmark Ed). 2014 Jun 1;19:1065-87. Review.

PMID:
24896337
6.

Galectin-1, a gene preferentially expressed at the tumor margin, promotes glioblastoma cell invasion.

Toussaint LG 3rd, Nilson AE, Goble JM, Ballman KV, James CD, Lefranc F, Kiss R, Uhm JH.

Mol Cancer. 2012 May 14;11:32. doi: 10.1186/1476-4598-11-32.

7.

Targeting the AKT pathway in glioblastoma.

McDowell KA, Riggins GJ, Gallia GL.

Curr Pharm Des. 2011;17(23):2411-20. Review.

PMID:
21827416
8.
9.

Molecular characterizations of glioblastoma, targeted therapy, and clinical results to date.

Bastien JI, McNeill KA, Fine HA.

Cancer. 2015 Feb 15;121(4):502-16. doi: 10.1002/cncr.28968. Epub 2014 Sep 23. Review.

10.

For the next trick: new discoveries in radiobiology applied to glioblastoma.

Debus J, Abdollahi A.

Am Soc Clin Oncol Educ Book. 2014:e95-9. doi: 10.14694/EdBook_AM.2014.34.e95. Review.

11.

Siomycin A targets brain tumor stem cells partially through a MELK-mediated pathway.

Nakano I, Joshi K, Visnyei K, Hu B, Watanabe M, Lam D, Wexler E, Saigusa K, Nakamura Y, Laks DR, Mischel PS, Viapiano M, Kornblum HI.

Neuro Oncol. 2011 Jun;13(6):622-34. doi: 10.1093/neuonc/nor023. Epub 2011 May 9.

12.

New molecularly targeted therapies for glioblastoma multiforme.

Polivka J Jr, Polivka J, Rohan V, Topolcan O, Ferda J.

Anticancer Res. 2012 Jul;32(7):2935-46. Review.

PMID:
22753758
13.

Antiangiogenic therapies in glioblastoma multiforme.

McNamara MG, Mason WP.

Expert Rev Anticancer Ther. 2012 May;12(5):643-54. doi: 10.1586/era.12.35. Review.

PMID:
22594899
14.

Therapeutic strategies for inhibiting invasion in glioblastoma.

Drappatz J, Norden AD, Wen PY.

Expert Rev Neurother. 2009 Apr;9(4):519-34. doi: 10.1586/ern.09.10.

PMID:
19344303
15.

Genetics of glioblastoma: a window into its imaging and histopathologic variability.

Belden CJ, Valdes PA, Ran C, Pastel DA, Harris BT, Fadul CE, Israel MA, Paulsen K, Roberts DW.

Radiographics. 2011 Oct;31(6):1717-40. doi: 10.1148/rg.316115512. Review.

PMID:
21997991
16.

QnAs with Ronald DePinho. Interview by Prashant Nair.

DePinho R.

Proc Natl Acad Sci U S A. 2013 Sep 3;110(36):14508-9. doi: 10.1073/pnas.1311541110. Epub 2013 Jul 18. No abstract available.

17.

Identification of novel small-molecule inhibitors of glioblastoma cell growth and invasion by high-throughput screening.

Wang L, Zhao H, Cui K, Yao L, Ren M, Hao A, Smollen P, Nie F, Jin G, Liu Q, Wong ST.

Biosci Trends. 2012 Aug;6(4):192-200.

18.

Glioblastoma: molecular analysis and clinical implications.

Huse JT, Holland E, DeAngelis LM.

Annu Rev Med. 2013;64:59-70. doi: 10.1146/annurev-med-100711-143028. Epub 2012 Oct 1.

PMID:
23043492
19.

Toward precision medicine in glioblastoma: the promise and the challenges.

Prados MD, Byron SA, Tran NL, Phillips JJ, Molinaro AM, Ligon KL, Wen PY, Kuhn JG, Mellinghoff IK, de Groot JF, Colman H, Cloughesy TF, Chang SM, Ryken TC, Tembe WD, Kiefer JA, Berens ME, Craig DW, Carpten JD, Trent JM.

Neuro Oncol. 2015 Aug;17(8):1051-63. doi: 10.1093/neuonc/nov031. Epub 2015 May 1. Review.

20.

Significance of interleukin-13 receptor alpha 2-targeted glioblastoma therapy.

Thaci B, Brown CE, Binello E, Werbaneth K, Sampath P, Sengupta S.

Neuro Oncol. 2014 Oct;16(10):1304-12. doi: 10.1093/neuonc/nou045. Epub 2014 Apr 10. Review.

Items per page

Supplemental Content

Write to the Help Desk